Transgenic mouse models of human cancers present unique opportunities to elucidate important cellular and genetic pathways of cancer development, through which normal cells progressively are converted into aberrant cancers. The overall goal of this proposal is to identify cellular signaling pathways impacting tumor development regulated by collagenolytic matrix metalloproteinases (MMPs) and their major stromal substrate, type I collagen, during squamous neoplastic progression in the skin. We will address the characteristics and functional significance of epithelial-stromal interactions regulated by collagenolytic MMPs and type I collagen by combined in vivo and in vitro approaches.
The specific aims of this proposal are:
Aim 1. Determine the mechanism(s) of type I collagen remodeling during tumor progression. We will determine the expression, localization, and activity of collagenolytic enzymes, and expression, synthesis, and degradation characteristics of type I collagen by molecular, biochemical, morphologic, and histochemical criteria during the development and metastasis of epithelial cancer in a transgenic mouse model of squamous carcinoma development.
Aim 2. Determine the consequences of altered type I collagen degradation in vivo: Altered substrate susceptibility. We will determine the impact of collagenaseresistant type I collagen on neoplastic progression, tumorigenesis, tumor stroma development, and the local metastasis of cancers in HPV16 transgenic mice.
Aim 3. Determine the consequences of type I collagen remodeling on cell behavior. We will determine the functional consequences of type I collagen remodeling on epithelial and endothelial cell behavior by combined in vivo and in vitro analyses. These studies will reveal the molecular and cellular mechanisms engaged by different populations of cells resulting from type I collagen remodeling during multi-stage neoplastic progression. The immediate ramifications of this work are in its applications to use of MMP-Inhibitors (MPIs) as anticancer agents and will provide proof-of-principle that eliminating productive access to a critical MMP substrate is an efficacious intervention for neoplastic progression. Only a thorough understanding of the actions and effects of MMPs and their major substrates will effectively guide use of MPIs in the treatment of cancer. ? ?
| Lund, Amanda W; Medler, Terry R; Leachman, Sancy A et al. (2016) Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer. Cancer Discov 6:22-35 |
| Sounni, Nor E; Dehne, Kerstin; van Kempen, Leon et al. (2010) Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech 3:317-32 |
| Andreu, Pauline; Johansson, Magnus; Affara, Nesrine I et al. (2010) FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17:121-34 |
| Sista, Akhilesh K; Knebel, Robert J; Tavri, Sidhartha et al. (2009) Optical imaging of the peri-tumoral inflammatory response in breast cancer. J Transl Med 7:94 |
| DeNardo, David G; Barreto, Jairo B; Andreu, Pauline et al. (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16:91-102 |
| Wolf, Katarina; Alexander, Stephanie; Schacht, Vivien et al. (2009) Collagen-based cell migration models in vitro and in vivo. Semin Cell Dev Biol 20:931-41 |
| Watkins, Gregory A; Jones, Ella Fung; Scott Shell, M et al. (2009) Development of an optimized activatable MMP-14 targeted SPECT imaging probe. Bioorg Med Chem 17:653-9 |
| Kenny, Hilary A; Kaur, Swayamjot; Coussens, Lisa M et al. (2008) The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 118:1367-79 |
| Johansson, Magnus; Denardo, David G; Coussens, Lisa M (2008) Polarized immune responses differentially regulate cancer development. Immunol Rev 222:145-54 |
| Egeblad, Mikala; Shen, H-C Jennifer; Behonick, Danielle J et al. (2007) Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development. Dev Dyn 236:1683-93 |
Showing the most recent 10 out of 17 publications
